Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine. Herein, we elucidated the dynamics of various...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandhu, Yuuki, Harada, Norihiro, Sasano, Hitoshi, Harada, Sonoko, Ueda, Shoko, Takeshige, Tomohito, Tanabe, Yuki, Ishimori, Ayako, Matsuno, Kei, Abe, Sumiko, Nagaoka, Tetsutaro, Ito, Jun, Chiba, Asako, Akiba, Hisaya, Atsuta, Ryo, Izuhara, Kenji, Miyake, Sachiko, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046637/
https://www.ncbi.nlm.nih.gov/pubmed/36979473
http://dx.doi.org/10.3390/biom13030538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046637/
https://www.ncbi.nlm.nih.gov/pubmed/36979473
http://dx.doi.org/10.3390/biom13030538

Ejemplares similares